SNOA

Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025 Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025 EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2026 and the fourth quarter ended March 31, 2026. "Fiscal 2026 was a year of significant progress for Sonoma," remarked Amy Trombly, CEO of Sonoma. "We delivered strong revenue growth while continuing to improve the financial health of the business as we maintained our focus on strategic growth, operational discipline, cost management, and efficient execution. Throughout the year, we continued to expand commercial partnerships, advance regulatory initiatives, and invest in product innovation. As we look ahead, our priority remains building a stronger and more scalable business by focusing on opportunities that align with our strategic objectives, generate attractive returns, and support long-term shareholder value. We believe the growing adoption of hypochlorous acid across healthcare, consumer, and wellness markets continues to create meaningful opportunities for Sonoma, and we remain focused on translating those opportunities into sustainable growth and improved profitability." Recent Business Highlights Sonoma continued to expand its product offerings, grow its distribution network, and expand regulatory approvals for its products: In October 2025, Sonoma announced the registration of its manufacturing facility and listing of its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Also in October 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States. In August 2025, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Psoriasis Foundation (NPF) Seal of Recognition, and in November 2025, Reliefacyn earned the National Rosacea Society (NRS) Seal of Acceptance. Results for the Quarter Ended March 31, 2026 Total revenue of $5.6 million for the fourth quarter of fiscal year 2026 increased by $1.8 million, or 48%, from $3.8 million for the same period last year. This increase was primarily due to increased revenues in the United States, Europe and Rest of World, partially offset by declines in Asia and Latin America due to timing of customer orders. United States revenue of $2.0 million for the fourth quarter ended March 31, 2026 increased by $1.3 million, or 194%, from $0.7 million for the same period last year due to increased sales by new distributors selling our products. During the fourth quarter of fiscal year 2026, Sonoma reported total revenues of $5.6 million and total cost of revenues of $3.4 million resulting in total gross profit of $2.2 million, or 39% of total revenue, compared to a gross profit of $1.5 million, or 41% of total revenue, in the same period last year. Total operating expenses during the fourth quarter of fiscal year 2026 were $2.5 million, up $0.3 million, or 16%, as compared to the same period in the prior year. This increase was primarily due to inflation and salary-related increases in Mexico. Net loss for the fourth quarter of fiscal year 2026 was $0.6 million, down by $0.2 million, or 25%, compared to the same period last year. EBITDA loss for the fourth quarter of fiscal year 2026 of $0.2 million was down by $0.3 million, or 66%, compared to an EBITDA loss of $0.5 million for the same period last year. As of March 31, 2026, Sonoma had cash and cash equivalents of $2.4 million. Results for the Year Ended March 31, 2026 Total revenues for fiscal year 2026 of $19.5 million increased by $5.2 million as compared to $14.3 million for the year ended March 31, 2025. The increase in revenue was driven primarily by increased revenues in all regions except Latin America due primarily to increased demand for our products. The decrease in Latin America was due to timing of customer orders. For fiscal year 2026, Sonoma reported total revenues of $19.5 million and total cost of revenues of $12.1 million, resulting in total gross profit of $7.4 million, or 38% of total revenues, compared to a gross profit of $5.5 million, or 38% of total revenues, for the same period in the prior year. Total operating expenses during fiscal year 2026 were $9.9 million, up $0.7 million, or 8%, as compared to the same period in the prior year. This increase was primarily due to market and inflation driven salary increases in Mexico. Net loss during fiscal year 2026 was $3.2 million, down $0.3 million, or 8%, compared to the same period last year. EBITDA loss for fiscal year 2026 of $2.1 million was down $1.2 million, or 38%, compared to an EBITDA loss of $3.3 million for the same period last year. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected]. Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. [email protected] Website: www.sonomapharma.com Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals Follow us on Instagram: https://www.instagram.com/sonomapharma_us/ Follow us on Facebook: https://www.facebook.com/sonomapharma/   SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESRECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES(In thousands)(Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIESREVENUE SCHEDULES(In thousands) The following table shows the Company's revenues by geographic region: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior year Net loss and net loss per share decreased from prior year for both the three months and nine months ended December 31, 2025 EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025 compared to prior year BOULDER, COLORADO / ACCESS Newswire / February 10, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2025. "Sonoma is pleased to report another quarter of revenue growth, demonstrating continued execution of our strategic priorities," remarked Amy Trombly, CEO of Sonoma Pharmaceuticals. "We are continuing to strengthen our regulatory position in both the U.S. and international markets and to broaden our distribution network. We have also strengthened our leadership and governance by welcoming a new Audit Committee Chair and a Senior Vice President of Regulatory, Quality and Product Development, as we position Sonoma for long-term global leadership in hypochlorous acid." Business Highlights Sonoma continued to advance its regulatory initiatives, expand distribution channels, and strengthen its organizational leadership: On October 7, 2025, Sonoma announced that it had successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). On October 14, 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States. On November 13, 2025, Sonoma announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society (NRS) Seal of Acceptance. On January 28, 2026, Sonoma announced the appointment of Vanessa Jacoby to its Board of Directors and Arturo Angel as its Senior Vice President of Regulatory, Quality and Product Development. Results for the Quarter Ended December 31, 2025 Revenues for the quarter ended December 31, 2025 of $4.3 million increased by $0.7 million, or 22%, compared to $3.6 million for the same period last year. Revenues in the U.S. increased 98%, primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Europe revenues increased 24% as a result of increased demand for our products. Revenues in Asia increased 38% and Rest of World revenues decreased 11%. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. Latin America revenues decreased 38%, primarily due to timing of customer orders for overflow manufacturing. For the quarter ended December 31, 2025, Sonoma reported revenues of approximately $4.3 million and cost of revenues of $2.7 million, resulting in gross profit of $1.6 million, or 38% of revenue, compared to a gross profit of $1.3 million, or 36% of revenue, for the same period last year. Gross margins increased by 2% for the quarter ended December 31, 2025 when compared to the same period last year as a result of an increase in revenue and overall product mix. Total operating expenses during the quarter ended December 31, 2025 were $2.3 million, approximately flat when compared to $2.3 million during the same period in the prior year. Net loss before income taxes for the quarter was $0.9 million, compared to $0.9 million for the same period last year. EBITDAS loss for the quarter ended December 31, 2025 of $0.6 million decreased by $0.4 million, compared to an EBITDAS loss of $1.0 million for the same period last year. Results for the Nine Months Ended December 31, 2025 Revenues of $14.0 million for the nine months ended December 31, 2025 increased by $3.5 million, or 33%, compared to $10.5 million for the same period last year. Revenues in the U.S. increased 90%, primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Europe revenues increased 31% as a result of increased demand for our products. Revenues in Asia increased 38% and Rest of World revenues increased 50%. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. Latin America revenues decreased 26%, primarily due to timing of customer orders for overflow manufacturing. For the nine months ended December 31, 2025, Sonoma reported revenues of $14.0 million and cost of revenues of $8.8 million, resulting in gross profit of $5.2 million, or 37% of revenues, compared to a gross profit of $3.9 million, or 37% of revenues, in the same period last year. Total operating expenses during the nine months ended December 31, 2025 of $7.3 million increased by $0.3 million, or 5%, compared to $7.0 million during the same period last year. Net loss before income taxes for the nine months ended December 31, 2025 was $2.9 million, compared to $2.4 million for the same period in the prior year. EBITDAS loss for the nine months ended December 31, 2025 of $1.9 million decreased by $0.9 million, compared to an EBITDAS loss of $2.8 million for the same period last year. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected]. Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. [email protected] Website: www.sonomapharma.com Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals Follow us on Instagram: https://www.instagram.com/sonomapharma_us/ Follow us on Facebook: https://www.facebook.com/sonomapharma/ SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (In thousands) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES PRODUCT RELATED REVENUE SCHEDULES (In thousands) (Unaudited) The following table presents the company's disaggregated product revenues by geographic region: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year BOULDER, CO / ACCESS Newswire / November 4, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2025. "We are thrilled to report the highest quarterly revenues in Sonoma's history - $5.6 million for the three months ended September 30, 2025," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "This achievement reflects the exceptional work of our team in expanding our distribution network, launching new products, and obtaining key regulatory clearances. While we anticipate some quarterly fluctuations as we continue to grow, we expect Sonoma's overall trajectory to be strongly positive, with increasing adoption of our high-quality products by both consumers and healthcare providers and solidification of our position as the global leader in the HOCl industry." Business Highlights Sonoma continued to improve and expand its product offerings and regulatory approvals, and to grow its distribution network by entering into new partnerships: On August 13, 2025, Sonoma announced the launch of its HOCl-based diaper rash products for infants and children into Walmart stores and other large retailers in the United States. On August 26, 2025, Sonoma announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel had earned the National Psoriasis Foundation (NPF) Seal of Recognition. On October 7, 2025, Sonoma announced that it had successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). On October 14, 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States. Results for the Quarter Ended September 30, 2025 Total revenues for the quarter ended September 30, 2025 of $5.6 million increased by $2.0 million, or 57%, as compared to $3.6 million for the same period last year. Revenues in the United States increased 115% primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Revenues in Europe increased 43% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues in Latin America increased 14% as a result of an increase in manufacturing orders. Revenues also increased in Asia and Rest of World when compared to the same period last year based on increasing demand. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. During the quarter ended September 30, 2025, Sonoma reported revenues of $5.6 million and cost of revenues of $3.5 million resulting in gross profit of $2.1 million, or 38% of revenue, compared to a gross profit of $1.4 million, or 38% of revenue in the same period last year. The increase is primarily the result of an increase in revenue as compared to last year. Total operating expenses during the quarter ended September 30, 2025 were $2.5 million, an increase of $0.2 million. Net loss for the three months ended September 30, 2025 of $0.5 million decreased by $0.1 million, or 12%, when compared to a net loss of $0.6 million for the three months ended September 30, 2024. EBITDA loss for the three months ended September 30, 2025 of $0.2 million decreased $0.4 million, compared to an EBITDA loss of $0.6 million for the same period last year. Results for the Six Months Ended September 30, 2025 Total revenues for the six months ended September 30, 2025 of $9.6 million increased by $2.6 million, or 38%, as compared to $7.0 million for the same period last year. Revenues in the United States increased 86% primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Revenues in Europe increased 30% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues in Latin America decreased 19% as a result of a decrease in manufacturing orders. Revenues increased in Asia and Rest of World when compared to the same period last year. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. During the six months ended September 30, 2025, Sonoma reported revenues of $9.6 million and cost of revenues of $6.0 million, resulting in gross profit of $3.6 million, or 37% of revenue, compared to a gross profit of $2.7 million, or 38% of revenue in the same period last year. The decrease is the result of changes in overall product mix and territories to which products were shipped. Total operating expenses during the six months ended September 30, 2025 were $5.0 million and increased by $0.3 million over prior year. Net loss for the six months ended September 30, 2025 of $1.8 million was flat when compared to a net loss of $1.8 million for the six months ended September 30, 2024. EBITDA loss for the six months ended September 30, 2025 of $0.8 million decreased $0.9 million, compared to an EBITDA loss of $1.7 million for the same period last year. As of September 30, 2025, Sonoma had cash and cash equivalents of $3.0 million. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected]. Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. [email protected] Website: www.sonomapharma.com Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals Follow us on Instagram: https://www.instagram.com/sonomapharma_us/ Follow us on Facebook: https://www.facebook.com/sonomapharma/ SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (In thousands) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES PRODUCT RELATED REVENUE SCHEDULES (In thousands) (Unaudited) The following table shows our consolidated total revenue and revenue by geographic region for the three and six months ended September 30, 2025 and 2024: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Revenues increased 18% compared to same period last year U.S. revenue increased 57% compared to same period last year Net loss per share decreased 43% compared to same period last year BOULDER, COLORADO / ACCESS Newswire / August 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2025. "We are pleased to report continued substantial revenue growth as we begin our fiscal year 2026," remarked Amy Trombly, CEO of Sonoma. "Several of our strategic initiatives contributed to this result including expanding our consumer-focused product portfolio, increasing our number of partners and broadening our regulatory portfolio. Additionally, our existing business showed organic growth. Sonoma continues to lead the industry by innovating safe, effective products that consumers want with an unparalleled global regulatory portfolio." Business Highlights Sonoma continued to grow its distribution network, expand its product offerings and expand regulatory approvals in its first fiscal quarter of 2026: In July 2025, Sonoma expanded its recent partnership for the sale of Microcyn technology-based products to one of the largest retailers in the United States to include additional consumer-focused products. In April 2025, Sonoma launched the sale of its hypochlorous acid-based acne products in over 1,200 stores in the United Kingdom through a leading U.K. health and beauty retailer and pharmacy chain. In April 2025, Sonoma received regulatory approval for the sale of its wound care products in Ukraine as a Class IIb medical device. Results for the Quarter Ended June 30, 2025 Total revenues for the quarter ended June 30, 2025 of $4.0 million were up $0.6 million as compared to $3.4 million for the same period last year. The increase in United States revenue of $363,000, or 57%, for the three months ended June 30, 2025 was primarily as a result of an increase in revenue related to the sale of human health care products and over-the-counter animal health care products. Revenues in Europe increased $180,000, or 14%, compared to the same period last year as the result of increased demand for Sonoma's products. Revenues increased in Asia and Rest of World when compared to the same period last year. These revenues tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs. Latin America revenue declined for the quarter ended June 30, 2025, compared to the same period last year due to timing of customer orders for overflow manufacturing. During the quarter ended June 30, 2025, Sonoma reported revenues of $4.0 million and cost of revenues of $2.5 million resulting in gross profit of $1.5 million, or 36% of revenue, compared to a gross profit of $1.3 million, or 39% of revenue, in the same period last year. Total operating expenses during the quarter ended June 30, 2025 were $2.6 million compared to $2.5 million in the same period last year due to an increase in research and development expenses. Net loss for the quarter of $1.2 million was nearly flat when compared to a net loss of $1.1 million for the quarter ended June 30, 2024. EBITDA loss for the quarter ended June 30, 2025 of $1.0 million remained approximately flat compared to an EBITDA loss of $1.0 million for the same period last year. As of June 30, 2025, Sonoma had cash and cash equivalents of $3.6 million. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected]. Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. [email protected] Website: www.sonomapharma.com Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals Follow us on Instagram: https://www.instagram.com/sonomapharma_us/ Follow us on Facebook: https://www.facebook.com/sonomapharma/ SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (In thousands) (Unaudited) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES PRODUCT RELATED REVENUE SCHEDULES (In thousands) (Unaudited) The following table shows consolidated total revenue and revenue by geographic region for the three months ended June 30, 2025 and 2024: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024 Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024 EBITDA loss improved 59% in Q4 2025 compared to Q4 2024, and 17% in FY 2025 compared to FY 2024 BOULDER, CO / ACCESS Newswire / June 17, 2025 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2025 and the fourth quarter ended March 31, 2025. "We are very pleased to report the results of our 2025 fiscal year and fourth fiscal quarter, which show continued revenue growth and consistent progress towards profitability," said Amy Trombly, CEO of Sonoma. "The successful transitioning of our products to the new Medical Device Regulation in the EU, well ahead of the 2028 deadline, and the registration of our products with the MHRA in the United Kingdom represent significant achievements for the Sonoma. We believe the strategic expansion of our sales and distribution network in the U.S. and internationally, supported by aggressive pursuit of worldwide regulatory approvals in new markets, is a winning formula." Recent Business Highlights Sonoma continued to expand regulatory approvals for its products, grow its distribution network, and expand its product offerings: Sonoma successfully transitioned all of its commercialized products in Europe to the new European Union (EU) Medical Device Regulation (MDR) ahead of the deadline for compliance, including its eye care, wound care, scar gel, acne, and atopic dermatitis products. Sonoma's manufacturing facility and five of its products were successfully registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom, including its wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant. In April 2025, Sonoma launched the sale of its hypochlorous acid-based acne products in over 1,200 stores in the United Kingdom through a leading U.K. health and beauty retailer and pharmacy chain. In March 2025 and June 2025, Sonoma expanded its recent partnership for the sale of Microcyn technology-based products to large retailers in the United States to include additional consumer-focused products. In April 2025, Sonoma received regulatory approval for the sale of its wound care products in Ukraine as a Class IIb medical device. Results for the Quarter Ended March 31, 2025 Total revenue of $3.8 million for the fourth quarter ended March 31, 2025 increased by $0.4 million, or 9%, from $3.4 million for the same period last year. This increase was primarily due to increased revenues in Europe and Latin America, partially offset by a decline in U.S. revenue due to fluctuations in demand for over-the-counter animal health care products and decreased revenues in Asia due to timing of customer orders. During the quarter ended March 31, 2025, Sonoma reported cost of revenues of $2.2 million resulting in total gross profit of $1.5 million, or 41% of total revenue, compared to a gross profit of $1.1 million, or 32% of total revenue, in the same period last year. Total operating expenses during the fourth quarter of fiscal year 2025 were $2.2 million, down $0.3 million, or 13%, as compared to the same period in the prior year. This decrease was primarily due to ongoing efforts to contain expenses across all parts of the company. Net loss for the fourth quarter of fiscal year 2025 was $0.8 million, down by $0.3 million, or 27%, compared to the same period last year. EBITDA loss for the fourth quarter of fiscal year 2025 of $0.5 million was down by $0.8 million, or 59%, compared to an EBITDA loss of $1.3 million for the same period last year. As of March 31, 2025, Sonoma had cash and cash equivalents of $5.4 million. Results for the Year Ended March 31, 2025 Total revenues for the year ended March 31, 2025 of $14.3 million increased by $1.6 million as compared to $12.7 million for the year ended March 31, 2024. The increase in revenue was driven primarily by increased revenues in Europe and Latin America, partially offset by a decline in U.S. revenue due to fluctuations in demand for over-the-counter animal health care products. For the year ended March 31, 2025, Sonoma reported total revenues of $14.3 million and total cost of revenues of $8.8 million, resulting in total gross profit of $5.5 million, or 38% of total revenues, compared to a gross profit of $4.7 million, or 37% of total revenues, for the same period in the prior year. Total operating expenses during fiscal year 2025 were $9.2 million, down $0.3 million, or 3%, as compared to the same period in the prior year. This decrease was primarily due to ongoing efforts to contain expenses across all parts of the company. Net loss during fiscal year 2025 was $3.5 million, down $1.4 million, or 29%, compared to the same period last year. EBITDA loss for fiscal year 2025 of $3.3 million was down $0.7 million, or 17%, compared to an EBITDA loss of $4.0 million for the same period last year. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected]. Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. [email protected] Website: www.sonomapharma.com Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals Follow us on Instagram: https://www.instagram.com/sonomapharma_us/ Follow us on Facebook: https://www.facebook.com/sonomapharma/ SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands, except share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (In thousands) (Unaudited) (1) Loss from operations minus non-cash expenses (EBITDA) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. (2) Net loss minus non-cash and one-time expenses is a non-GAAP financial measure. The company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes, and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. (3) Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES REVENUE SCHEDULES (In thousands) The following table shows the Company's revenues by geographic region: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire